Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: keithcray who wrote (448)	6/21/2001 1:47:29 PM
From: 2MAR$	Respond to of 208838

GENE ran up again ---> to Present at BIO 2001 International Investor & Partnering Forum WALTHAM, Mass., Jun 21, 2001 /PRNewswire via COMTEX/ -- Genome Therapeutics Corporation (Nasdaq: GENE) will present an update of the Company's progress, alliances and growth strategy at 12:45 p.m. (EST) on Tuesday, June 26 in San Diego, Calif. CEO and President Steven M. Rauscher will update investors on the Company's six genomics-based alliances, growing services business and internal drug discovery programs. Individuals can access the live audio of this presentation through the link below: informedinvestors.com After logging onto the Informed Investors website, look for Genome Therapeutics under the list of presenting companies. Genome Therapeutics (www.genomecorp.com) is a genomics-based drug discovery company operating two lines of business: genomics services and biopharmaceutical. The genomics services business focuses on services that enable other organizations to achieve their drug discovery objectives and includes the GTC Sequencing Center and the PathoGenome(TM) Database. The biopharmaceutical business focuses on the development of novel therapeutics, vaccines and diagnostics to solve major medical needs, includes six alliances with pharmaceutical companies (Schering-Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux) and a joint venture with ArQule. SOURCE Genome Therapeutics CONTACT: Christopher Taylor, Sr. Director, Investor Relations, 781-398-2466, or Amy Steele, Corporate Communications, 781-39 -2594, both of Genome Therapeutics Corporation URL: genomecorp.com prnewswire.com Copyright (C) 2001 PR Newswire. All rights reserved. -0- KEYWORD: Massachusetts California INDUSTRY KEYWORD: MTC BIO FIN * end of story *